Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16379304 | 1.00 | HDAC1 (0.31) | HDAC1HDAC2HDAC6CA12CA1 | |
| SCHEMBL16284716 | 0.92 | CA14 (0.33) | HDAC1HDAC2HDAC6CA12CA1 | |
| SCHEMBL17369159 | 0.83 | CA1 (0.37) | HDAC1HDAC2HDAC6CA12CA1 | |
| SCHEMBL16379305 | 0.83 | CA1 (0.37) | HDAC1HDAC2HDAC6CA12CA1 | |
| SCHEMBL23610157 | 0.83 | HDAC6 (0.36) | HDAC1HDAC2HDAC6CA14 | |
| SCHEMBL23610090 | 0.81 | HDAC6 (0.32) | HDAC1HDAC2HDAC6 | |
| SCHEMBL23610091 | 0.81 | HDAC6 (0.32) | HDAC1HDAC2HDAC6 | |
| SCHEMBL2390690 | 0.81 | CA14 (0.42) | HDAC1HDAC2HDAC6CA12CA1 | |
| SCHEMBL15418769 | 0.81 | CA14 (0.42) | HDAC1HDAC2HDAC6CA12CA1 | |
| SCHEMBL27041570 | 0.81 | CA14 (0.42) | HDAC1HDAC2HDAC6CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926298-B2 | Heterocyclic compounds and use thereof | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2018-03-27 | — | — | US | disclosed |
| US-20180009786-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RES INST (TW) | 2018-01-11 | — | — | US | disclosed |
| US-9862703-B2 | Heterocyclic compounds and use thereof | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2018-01-09 | — | — | US | disclosed |
| US-20160083369-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | NAT HEALTH RESEARCH INSTITUTES (TW) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009786-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | CXCL12, HPGDS, MCL1 | HDAC1 171/4885HDAC2 678/4885HDAC6 229/4885 |
| US-20160083369-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | CXCL12, HPGDS, MCL1 | HDAC1 171/4885HDAC2 678/4885HDAC6 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.